AAPG (Ascentage Pharma Corp) Earnings per share growth rate in current year
High regulatory risks regarding drug approval create volatility, which the year-over-year earnings per share change on the GURU.Markets chart visualizes through the value 74.70, capturing this metric for Ascentage Pharma Group (AAPG). Capital resilience is based on global distribution contracts, while the potential for leadership in oncology is driven by unique patents for triggering cancer cell apoptosis.
Financial and market metric breakdowns for Ascentage Pharma Corp (AAPG)
- stock price and consensus target price:
- business market valuation indicators:
- balance sheet equity data:
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Ascentage Pharma Group|AAPG - Long-Term Debt to Capital|Current Liabilities to Capital Ascentage Pharma Group International|AAPG - Company Debts|Debt to Book Value Ratio Ascentage Pharma Group International|AAPG - Company Long-Term Liabilities|Amount of Current Liabilities Ascentage Pharma|Quick Ratio ascentage.com
- earnings and market multiples details:
AAPG - Net Profit|Projected Net Profit Ascentage Pharma Group|AAPG - P/E Multiple|Projected Price to Earnings Ratio Ascentage Pharma|AAPG - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Ascentage Pharma Group|AAPG - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Ascentage Pharma|AAPG - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months ascentage.com|AAPG - Earnings growth in current year|Earnings growth forecast for next year Ascentage Pharma Group
- revenue and sales proceeds data:
Basic company analysis:Ascentage Pharma Group
This metric measures the year-over-year dynamics of earnings per share, allowing investors to evaluate capital management efficiency and business scaling rates. By analyzing the tracking of annual EPS growth, one can determine the financial stability of Ascentage Pharma Group (AAPG) in developing costly targeted oncology drugs for the therapy of resistant tumors, where high development costs necessitate strict control of operating expenses.
Key competitors
Earnings per share growth rate in current year BeiGene Corp (ONC)|HALO (Halozyme Therapeutics, Inc.) - Earnings growth in current year|Earnings per share growth rate in current year revmed.com RVMD|Earnings growth in current year CGON|Earnings growth in current year UroGen Pharma Ltd (URGN)|Earnings growth in current year BCAX (Bicara Corp)|Personalis Genomics (PSNL) - Earnings per share growth rate in current year|Erasca Oncology - Earnings growth in current year|DCTH: Earnings per share growth in current year|YMAB: Earnings growth in current year|Aura Bio (AURA) - Earnings growth in current year|CADL (Candel Therapeutics Inc.) - Earnings growth in current year|ARAY: Earnings per share increase in current year|Net earnings per share growth this year SLS (SELLAS Life Sciences Group, Inc.)|Net earnings per one share growth for the current year ACTU|Citius Oncology - Net earnings per share growth this year|Earnings per share increase in current year HURA|TARA: Net earnings per share growth this year|Earnings per share growth rate in current year Fate Pharma|Aadi Bioscience Inc (WHWK) - Earnings per share growth in current year|Earnings per share growth rate in current year TScan (TCRX)|Net earnings per share growth this year CSBR|xbiotech.com (XBIT) - Expected net earnings per share growth this year|Earnings per share growth in current year cel-sci.com (CVM)|OSTX - Earnings per share growth rate in current year|Radiopharm Theranostics - Net earnings per share growth this year|Earnings per share increase in current year ARTV|ANL - Earnings per share growth in current year|VERU - Earnings growth in current year|Tempest Therapeutics, Inc. (TPST) - Earnings per share growth in current year|XLO: Net earnings per one share growth for the current year|RENB (Renovaro Biosciences) - Earnings growth in current year|MURA: Earnings per share increase in current year|Net earnings per share growth this year KAPA (Kairos Pharma Ltd)|Net earnings per one share growth for the current year OKUR|CytoMed Therapeutics Limited - Net earnings per share growth this year|CRIS: Earnings per share growth this year|APLM - Earnings per share growth in current year|THAR - Earnings growth in current year|ADVB: Earnings growth in current year|Earnings per share growth this year GNPX|CLDI (Calidi Biotherapeutics, Inc.) - Earnings growth in current year|Earnings per share growth in current year SBFM|Earnings growth in current year XBIO|Net earnings per share growth this year Salarius Pharmaceuticals SLRX|Earnings growth in current year PPBT (Purple Biotech Ltd)|AONC - Net earnings per share growth this year|BGNE: Net earnings per share growth this year|Expected net earnings per share growth this year Checkpoint Therapeutics, Inc CKPT|ELEV: Earnings growth in current year|Earnings per share growth rate in current year iCAD Inc. (ICAD)|IKNA (Ikena) - Earnings growth in current year|Net earnings per share growth this year Notable Labs (NTBL)|Earnings growth in current year VIRX|Net earnings per share growth this year MorphoSys Corporation MOR|NAYA Biosciences - Net earnings per share growth this year|Net earnings per share change in current year Ascentage Pharma
